Evaluation of DEMU La' farrerr Topical Cream Effect on Bruises Caused by Filler Injection

Comparative Efficacy Evaluation of a Topical Cream (DEMUlcent ™) Containing Arnica and Rosemary Extracts with Placebo on Filler-Injected Patients Bruise: A randomized Double-blind Control Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020250N7

Enrollment

Registered

2023-08-19

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bruising Caused by Nasolabial Filler Injection. Spontaneous ecchymoses (Petechiae). Excl: ecchymoses in fetus and newborn, purpura.

Interventions

Intervention 1: Intervention group: DEMUlcent Cream Containing Arnica, Rosemary, Chamomile and... Extracts La' farrerr in a white and unspecified Tube/Used for 14 days, Every 8 Hours at the Filler In

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Individuals Receiving Nasolabial Filler Injection or Facial Botox at Razi Hospital (With Bruises Caused by Filler Injection in the Face Area) Age between 18 and 65

Exclusion criteria

Exclusion criteria: Pregnancy Possibility or Having Plan for Pregnancy in the Next 3 Months Lactation Taking Aspirin and Other Anticoagulant Medicines Unwillingness to Participating in the Trial

Design outcomes

Primary

Measure	Time frame
Bruise Intensity by the Surface Area. Timepoint: Days 1, 2, 3, 4, 5, 7, 10 and 14. Method of measurement: Total bruised area measurement.;The stage (age) of bruises. Timepoint: Days 1, 2, 3, 4, 5, 7, 10 and 14. Method of measurement: Spot Color by Colorimetric Scale NNDV No. 2.;Bruise Control Time Period. Timepoint: Length of treatment period (14 days). Method of measurement: Clinical examination and review of images taken from the position.	—

Measure

Time frame

Bruise Intensity by the Surface Area. Timepoint: Days 1, 2, 3, 4, 5, 7, 10 and 14. Method of measurement: Total bruised area measurement.;The stage (age) of bruises. Timepoint: Days 1, 2, 3, 4, 5, 7, 10 and 14. Method of measurement: Spot Color by Colorimetric Scale NNDV No. 2.;Bruise Control Time Period. Timepoint: Length of treatment period (14 days). Method of measurement: Clinical examination and review of images taken from the position.

—

Secondary

Measure	Time frame
Pain feeling in the spot. Timepoint: Days 1, 2, 3, 4, 5, 7, 10 and 14. Method of measurement: The numeric rating scale (NRS).;Side Effects (Hypersensitivity or any other side effects not related to other treatments and medicines received by the patient). Timepoint: Length of treatment period (14 days). Method of measurement: Patient statements during examinations and other times.;Volume of filler injected to the site by ml. Timepoint: Day 0 (Filler injection). Method of measurement: ml of filler injected.	—

Measure

Time frame

Pain feeling in the spot. Timepoint: Days 1, 2, 3, 4, 5, 7, 10 and 14. Method of measurement: The numeric rating scale (NRS).;Side Effects (Hypersensitivity or any other side effects not related to other treatments and medicines received by the patient). Timepoint: Length of treatment period (14 days). Method of measurement: Patient statements during examinations and other times.;Volume of filler injected to the site by ml. Timepoint: Day 0 (Filler injection). Method of measurement: ml of filler injected.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDanial Mehrali

Tehran University of Medical Sciences

danielmehrali@gmail.com+98 21 64120

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026